Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)
Clinical trial NCT02650895 · COMPLETED
Trial details
- NCT number
- NCT02650895
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-06-02
- Primary completion
- 2015-01-15
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.